Home›Legal›Tirzepatide in Pennsylvania
Tirzepatide in Pennsylvania: Legal Status & Provider Guide (2026)
Quick Answer
Tirzepatide is a prescription substance in the United States. Tirzepatide is an FDA-approved dual GIP/GLP-1 receptor agonist. The compounding shortage exemption expired in early 2025. Current federal law generally prohibits compounded tirzepatide outside of narrow exceptions. Providers offering compounded tirzepatide should have clear documentation of their legal basis. In Pennsylvania, compounding is governed by the Pennsylvania State Board of Pharmacy (PSBP). Pennsylvania certified registered nurse practitioners (CRNPs) may prescribe compounded medications including peptides within a collaborative agreement. Physician assistants also require supervision agreements. Pennsylvania has moderately permissive telehealth rules, allowing prescribing after an appropriate telehealth evaluation. Pennsylvania prescribers must hold an active Pennsylvania license to prescribe to Pennsylvania residents.
Federal Legal Status
FDA Approval Status
FDA-approved as Mounjaro (type 2 diabetes, 2022) and Zepbound (chronic weight management, 2023). FDA declared the tirzepatide shortage resolved in December 2024.
Compounding Pharmacy Rules (Federal)
Compounded tirzepatide was broadly permitted during the shortage period. Following FDA's shortage resolution in December 2024, 503B outsourcing facilities had until February 18, 2025, and 503A pharmacies until March 19, 2025, to wind down compounding. As of mid-2025, compounded tirzepatide is generally prohibited except for narrow clinical exceptions under a valid prescription.
Also Known As
Mounjaro · Zepbound
Primary Research Areas
- Weight management
- Type 2 diabetes
- Metabolic health
- Insulin resistance
Pennsylvania Pharmacy Board & Compounding Rules
Compounding Overview
Pennsylvania's State Board of Pharmacy regulates compounding pharmacies with detailed sterile and non-sterile compounding standards. Pennsylvania has historically been home to several large-scale compounding operations. The state enforces USP 797 standards for sterile products and requires annual inspections for high-risk compounding. Pennsylvania is part of the northeastern corridor with significant demand from New York, New Jersey, and Delaware markets.
Notable Rules
- Pennsylvania requires pharmacies engaged in sterile compounding to have a separate license category.
- Annual inspections are required for pharmacies performing high-risk sterile compounding.
- Pennsylvania shares regulatory burden with the FDA for pharmacies also registered as 503B outsourcing facilities.
- Non-resident pharmacies shipping compounds into Pennsylvania must be registered with the PSBP.
- Pennsylvania and New York maintain some reciprocal licensing arrangements for pharmacy professionals.
Prescribing Requirements in Pennsylvania
Pennsylvania certified registered nurse practitioners (CRNPs) may prescribe compounded medications including peptides within a collaborative agreement. Physician assistants also require supervision agreements. Pennsylvania has moderately permissive telehealth rules, allowing prescribing after an appropriate telehealth evaluation. Pennsylvania prescribers must hold an active Pennsylvania license to prescribe to Pennsylvania residents.
About Tirzepatide
Tirzepatide is a novel dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptor agonist developed by Eli Lilly. It has demonstrated significant efficacy in clinical trials for both glycemic control and weight reduction, with some studies showing superior weight loss compared to semaglutide.
For more research information, mechanism of action, and provider availability, see the Tirzepatide research profile on PeptideBase.
Frequently Asked Questions
- Is compounded tirzepatide legal in 2026?
- FDA declared the tirzepatide shortage resolved in December 2024. Wind-down periods ended in Q1 2025. As of mid-2025, compounded tirzepatide is generally prohibited except for documented clinical exceptions. Patients should verify the legal basis with their provider.
- What is the difference between Mounjaro and Zepbound?
- Both contain tirzepatide. Mounjaro is FDA-approved for type 2 diabetes management; Zepbound is approved for chronic weight management in adults with obesity or overweight with a related condition. The drugs are chemically identical.
Tirzepatide Providers in Pennsylvania
No providers currently listed in Pennsylvania for Tirzepatide. Browse the full directory to find providers offering Tirzepatide.
Browse all Tirzepatide providers →Tirzepatide Legal Status in Other States
Pharmacy board rules and compounding regulations vary by state. Compare Tirzepatide legal status across other major markets:
Content review: This educational overview is prepared by the PeptideBase editorial team and reviewed for factual accuracy. Reviewer byline coming soon (gated on 4.4). Last updated: .